Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
about
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibA virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivoIGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.
P2860
Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Isotype-specific inhibition of ...... y in hematologic malignancies.
@en
type
label
Isotype-specific inhibition of ...... y in hematologic malignancies.
@en
prefLabel
Isotype-specific inhibition of ...... y in hematologic malignancies.
@en
P2093
P2860
P356
P1476
Isotype-specific inhibition of ...... y in hematologic malignancies.
@en
P2093
Benjamin Kuritzky
Kenneth D Bishop
Meera Iyengar
P2860
P304
P356
10.2147/OTT.S34641
P407
P577
2014-02-21T00:00:00Z